3Q Upside For Medical Tech. & Hospital Supplies
Piper Jaffray has published a research report on Medical Technology and Hospital Supplies as sales continue to track above expectations, as witnessed in September earnings results.
In the report, Piper Jaffray writes "JNJ: Tracking $24 MM ahead of expectations - Upside in Q3 is being driven
primarily by greater-than-expected share gains and growth by Simponi and Nucynta, albeit on relatively small prior-year comparisons. Additionally, sales of both Concerta and Prezista are tracking above our revenue estimates for the quarter, +$29 mil and +$28 mil, respectively. Offsetting the strength in these product lines is slight weakness in Respirdal Consta and Topamax, $7 mil and $3 mil, respectively, below our estimates.
• ACL: Tracking $39 MM above our estimates - By our analysis, upside for ACL in Q3 continues to be primarily driven by price taken at the beginning of the year and volume growth in Patanol/Pataday and CiproHC/Ciprodex, which are tracking approximately $16 mil and $23 mil, respectively, above our estimates. The rest of ACL's pharma products continue to track slightly above our expectations."
Companies related to this article include:
Alcon, Inc. (NYSE: ACL) $170.18
Johnson & Johnson (NYSE: JNJ) $63.58
